Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

Movement Disorders

Volumn 19, Issue 10, 2004, Pages 1183-1186

  Bara Jimenez, William ^a   Dimitrova, Tzvetelina ^a   Sherzai, Abdulah ^a   Favit, Antonella ^a   Mouradian, M M ^a   Chase, Thomas N ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Clinical trial; Dopamine; Dyskinesia; Levodopa; Parkinson's disease; Striatum; Transporter; Uptake

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE UPTAKE INHIBITOR; LEVODOPA; NS 2330; PLACEBO; PRAMIPEXOLE; ROPINIROLE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOPAMINE UPTAKE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HALLUCINATION; HEADACHE; HUMAN; HYPOTENSION; MALE; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYNAPTIC TRANSMISSION;

AGED; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CARBIDOPA; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; LEVODOPA; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PILOT PROJECTS; THIAZOLES;

EID: 7244224929     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20124     Document Type: Article

References (16)

1. Jaber M, Jones S, Giros B, Caron MG. The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 1997;12:629-633.
2. Elsworth JD, Roth RH. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp Neurol 1997;144:4-9.
3. Reith ME, Xu C, Chen NH. Pharmacology and regulation of the neuronal dopamine transporter. Eur J Pharmacol 1997;324:1-10.
4. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990;525:36-44.
5. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990;13:290-296.
6. Cragg SJ, Hille CJ, Greenfield SA. Dopamine release and uptake dynamics within nonhuman primate striatum in vitro. J Neurosci 2000;20:8209-8217.
7. Cragg SJ, Hille CJ, Greenfield SA. Functional domains in dorsal striatum of the nonhuman primate are defined by the dynamic behavior of dopamine. J Neurosci 2002;22:5705-5712.
8. Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000;47: S122-S130.
9. Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. Eur J Pharmacol 2002;451:157-160.
10. Thatte U. NS-2330 (Neurosearch). Curr Opin Investig Drugs 2001; 2:1592-1594.
11. Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-296.
12. Investigator's Drug Brochure. Neurosearch. March, 2000.
13. Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther 2002;303:952-958.
14. Goetz CG, Tanner CM, Klawans HL, Bupropion in Parkinson's disease. Neurology 1984;34:1092-1094.
15. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997;12:756-759.
16. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 1994;35:494-498.